Latest Research And Development News

Starpharma reports a $1.37 million profit for H1 FY26, driven by a major upfront payment from Genentech and progress in its radiopharmaceutical pipeline. The biotech also expands its consumer health footprint amid growing partnerships.

BCAL Diagnostics reported a slight revenue decline and a persistent net loss in its half-year results, with auditors flagging concerns over its ability to continue without additional funding.

Energy Action Limited reported a strong 20.1% revenue increase in the first half of FY26, driven by robust energy procurement activity, yet net profit after tax fell sharply due to higher amortisation and tax expenses.

Elixir Energy has successfully drilled the Lorelle-3 pilot well to 3,580 metres in Queensland’s Taroom Trough, intersecting multiple Permian hydrocarbon reservoirs including a thick section of the primary Tinowon ‘Dunk’ Sandstone. Wireline logging and upcoming stimulation tests aim to confirm commercial gas flow potential.

AVITA Medical reported a mixed fourth quarter with revenue pressures easing and full-year growth, underpinned by a new $60 million credit facility and advancing clinical trials.

AVITA Medical reported steady Q4 losses amid reimbursement challenges but achieved 11% revenue growth for 2025 and secured a $60 million credit facility to fuel future expansion.

St George Mining has won preferential tax treatment from the Minas Gerais government, cutting development costs for its flagship Araxá Project in Brazil. This support bolsters the company’s ambitions to establish a world-class niobium and rare earths operation.

Amaero Ltd reported a remarkable 367% revenue increase to A$7.76 million for H1 FY2026, supported by a $50 million capital raise and exclusive supply agreements with industry leaders. Despite widening losses, the company is accelerating capacity expansion and securing key partnerships in aerospace and defence.

Cochlear Limited reported a modest 1% rise in HY26 sales revenue to $1.176 billion, but underlying net profit fell 9% amid slower-than-expected contract renewals for its new Nucleus Nexa implant system. The company anticipates a stronger second half and maintains full-year guidance at the lower end of its forecast.

Cochlear Limited reported a modest 1% rise in sales but a 9% fall in underlying net profit for the half year ended December 2025, as the rollout of its innovative Nucleus Nexa System faced longer-than-expected regulatory and contract hurdles. The company anticipates a robust second half driven by broader product availability and service growth.

Cochlear Limited posted a modest 1% increase in sales revenue for the half year ending December 2025, while underlying net profit fell 9%, impacted by cloud computing costs and a slower-than-expected Nexa System rollout. The company maintains its dividend and outlines cautious FY26 guidance.

Breville Group Limited has reported a record half-year revenue of AUD 1.1 billion, overcoming US tariff challenges through strategic manufacturing shifts and robust product innovation. The company’s steady profitability and geographic expansion signal a confident growth trajectory.